8-K: GRI Bio Increases Share Offering to $1.76 Million Under At-The-Market Agreement

GRI Bio, Inc. has increased the maximum number of shares available under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC to $1,758,934.

Summary

• GRI Bio, Inc. filed a prospectus supplement on May 23, 2025, to increase the number of shares available under its At The Market Offering Agreement.
• The agreement with H.C. Wainwright & Co., LLC, dated May 20, 2024, now allows for the issuance of up to $1,758,934 of shares.
• This amount is in addition to the approximately $4,546,137 of shares already sold under the agreement.
• The company has obtained a legal opinion from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., regarding the legality of the issuance and sale of these shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard financial procedure for a company to raise capital, but it could lead to dilution.

Positives

• The increased share offering provides GRI Bio with additional financial flexibility.
• The legal opinion from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. supports the legality of the share issuance.

Risks

• The market may not respond favorably to the increased share offering, potentially diluting existing shareholders' equity.
• The company's reliance on the At The Market Offering Agreement for funding may indicate challenges in securing capital through other means.

Future Outlook

The company intends to continue utilizing the At The Market Offering Agreement to raise capital.

Industry Context

At-the-market offerings are a common method for small-cap biotech companies to raise capital, providing flexibility but also potentially signaling a need for funds.

Comparison to Industry Standards

• Many small-cap biotech companies use ATM offerings to raise capital, but the size and frequency can vary significantly.
• Comparable companies like XOMA Corporation and Catalyst Biosciences have also utilized ATM offerings in the past.
• The success of the offering will depend on market conditions and investor confidence in GRI Bio's pipeline.

Stakeholder Impact

• Shareholders may experience dilution due to the increased number of shares being issued.
• The company's ability to fund its operations and research programs may be enhanced.

Next Steps

• GRI Bio will continue to offer and sell shares through H.C. Wainwright & Co., LLC under the At The Market Offering Agreement.
• The company will use the proceeds from the share sales for general corporate purposes.

Key Dates

Keywords

At The Market Offering, Share Offering, GRI Bio, H.C. Wainwright, Prospectus Supplement, Common Stock